摘要:
p38 alpha MAP kinase is a key anti-inflammatory target for rheumatoid arthritis, influencing biosynthesis of pro-inflammatory cytokines TNF alpha and IL-1 beta at a translational and transcriptional level. In this paper, we describe how we have optimized a series of novel p38 alpha/beta inhibitors using crystal structures of our inhibitors bound to p38 alpha, classical medicinal chemistry, and modeling of virtual libraries to derive a molecule suitable for progression into clinical development.